Skip to content

Action-effect Anticipation in Patients With Parkinson's Disease : A Study of the Sensory Attenuation Marker.

The Process of Sensory Anticipation in Patients With PARKINSON's Disease

Status
Terminated
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02894333
Acronym
IDEOMOT
Enrollment
1
Registered
2016-09-09
Start date
2015-12-31
Completion date
2019-09-30
Last updated
2019-12-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson Disease

Keywords

Parkinson's disease, Action-effect prediction, Sensory attenuation, Voluntary action

Brief summary

The ideomotor theory of action control is considered to be central to the understanding of human voluntary action. According to the ideomotor theory, an action is represented in terms of its desired sensory effects and actions are selected by internally activating these effect representations. Recent imagery and behavioral studies showed that this anticipated representation of action-effects triggered a sensory attenuation, meaning a decrease of perceptive performances or a decrease of sensory event-related potentials (ERP) for an expected event. Thus, the sensory attenuation constitutes a relevant behavioral tool to investigate sensory anticipation impairment in patients with Parkinson's disease. In a behavioral paradigm, patients and matched control participants have to perform a perceptive task on predicted visual action-effects mixed with mispredicted visual action effects. Performances should be better in mispredicted visual action effects for control participants only.

Interventions

Sponsors

Fondation Ophtalmologique Adolphe de Rothschild
Lead SponsorNETWORK

Study design

Observational model
OTHER
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Parkinson's disease * Normal or corrected vision

Exclusion criteria

* Other pathology or neurological or psychiatric history * Known pregnancy or breastfeeding * Absence of affiliation to the French Social Security * Person under legal protection * Patient's opposition to participate

Design outcomes

Primary

MeasureTime frameDescription
median scorebaselinescores measured with the Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS)

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026